Introduction
Knee osteoarthritis (OA) involves cartilage degeneration, synovial inflammation, and subchondral bone thickening, resulting in pain and functional limitation. Total knee arthroplasty (TKA) is one of the treatment options for the final stages of the disease, reducing symptoms and restoring joint function. Implant design and fixation have progressively improved, leading to an increased survival and functionality. However, blood loss related to this procedure is still a concern that needs to be investigated and addressed. [1] [2] [3] [4] Blood loss control and prevention strategies include the use of pneumatic tourniquets, hypotensive anesthesia, blood transfusions, and pharmacological agents; the latter, however, may be related to complications inherent to their use.
5,6
Several studies using topical fibrin sealants, such as Quixil (Omrix Biopharmaceuticals, New York City, NY, USA) and Floseal (Baxter International, Deerfield, IL, USA), have shown their efficacy in reducing visible blood loss, total bleeding, and blood transfusion rates in TKAs. [7] [8] [9] [10] [11] However, these drugs may be related to thromboembolic and allergic complications due to the presence of clot-stabilizing agents in their formulas, such as tranexamic acid (TA) and aprotinin.
12
A new generation of fibrin sealants (Evicel, Johnson & Johnson, New Brunswick, NJ, USA), containing no such agents, was then developed.
13
The present study aimed to evaluate the intraoperative use of a topical human fibrin sealant free of clot stabilizers in TKA and its influence on blood loss, on blood transfusion requirements, on the length of hospital stay, on pain perception, on the range of motion (ROM), and on the incidence of complications.
Methods
The study population consisted of 64 patients submitted to TKA for primary knee OA treatment between September 2015 and April 2017.
Patients > 55 years old with at least 90°range of motion (ROM), with no significant angular deformities, and presenting OA radiographic changes graded 4 or 5 according to the Ahlback system were included in the study after signing the informed consent form. Complying with ethical standards, the present study was approved by the Institutional Ethics Board (protocol number 48370515.4.0000.5273).
Patients presenting with any risk factor predisposing to increased bleeding during or after surgery, such as coagulopathies, chronic kidney disease, continuous treatment with oral anticoagulants, and secondary OA, as well as those whose surgical procedure lasted > 2 hours, were excluded.
The sample size was determined by similar studies in the literature, 9 and allocation in 2 experimental groups, with 32 patients each, was performed by randomization using sealed envelopes. The envelopes were opened just prior to the closure of the wound, to avoid any kind of bias. Patients in the intervention group (Sealant) received a topical, 6 mL application of Evicel fibrin hemostatic agent, consisting of human fibrinogen (250 to 450 mg) and thrombin (4,000-6,000 IU); these chemicals come in 2 separate vials and they
Palavras-chave are combined through an application device. Patients in the control group (Control) received no product application. All of the selected patients underwent the same standard surgical technique (cemented unilateral primary TKA with posterior stabilization) under pneumatic ischemia; the procedure was performed by surgeons with > 5 years of experience. Three implant models were used: Press Fit Condylar Sigma DePuy-Synthes (Johnson & Johnson, New Brunswick, NJ, USA ), NexGen Knee Replacement System (Zimmer Biomet, Warsaw, IN, USA), and ACS Knee System (Implantcast, Hamburg, Germany).
The pneumatic cuff was kept inflated until the wound was completely closed, preventing blood loss throughout the surgical time. A single 4.8-mm intra-articular Hemovac (Zimmer Biomet, Warsaw, IN, USA) drain with negative suction was used in all of the patients and was maintained for 24 hours. Thromboembolic events were prevented in all of the patients through a single daily subcutaneous dose of 40 mg of low molecular weight heparin; this treatment was initiated 12 to 24 hours after the end of the procedure and was maintained for 15 days.
The hematimetric indexes were measured preoperatively, on the 1 st postoperative day (24 hours, n ¼ 63), and on the 3 rd postoperative day (60 to 72 hours, n ¼ 41) on those patients who had not yet been discharged. The following parameters were considered for blood loss analysis: blood volume, blood loss at the drain, hemoglobin loss, and total blood loss.
The blood volume of each patient was determined according to the Nadler formula.
14 The drained blood loss volume was determined by the blood volume (mL) collected by negative suction through the Hemovac drain within 24 hours after the procedure. Hemoglobin (Hb) loss after 24 hours was calculated using the formula:
Lost Hb ¼ [Hb at admission À Hb at discharge (24h)] þ transfused Hb Where:
1. Lost Hb ¼ total hemoglobin (g/dL) loss after the procedure 2. Hb at admission ¼ Hb (g/dL) Â volemia/100 3. Hb at discharge ¼ Hb (g/dL) Â volemia/100
Transfused Hb ¼ total hemoglobin (g/dL) amount transfused through packed red blood cell transfusion. Each blood bag from the institution and state blood bank contains a mean hemoglobin concentration of 60 g/bag (0.6 g/dL).
The loss of hemoglobin after 60 hours was calculated with the following formula:
The blood loss (mL) on the 1 st postoperative day (24 hours) was calculated by the following formula: Blood loss ¼ volemia Â lost Hb (24h)/Hb at admission The blood loss (mL) on the 3 rd postoperative day (60 hours) was calculated by the following formula: Blood Loss ¼ volemia Â lost Hb (60h)/Hb at admission Data from all of the patients who received blood transfusions and the number of blood components bags used in each one of them was recorded.
The total length of hospital stay was analyzed and compared between the groups. The discharge criteria were pain control with oral analgesic agents and the ability to walk with assistance, in addition to the absence of clinical complications.
Pain intensity was assessed in all of the patients through a visual analogue scale (VAS), whose score ranges from 1 to 10. The information was collected at the hospital, prior to surgery, and again on the 2 nd day and on the 6 th week after the procedure. The ROM was evaluated with the patient in the supine position using a standard goniometer.
Complications, such as wound healing problems, deep venous thrombosis, and superficial or deep infection, were recorded if identified.
All data were analyzed by GraphPad Prism 5 for Windows (GraphPad Software, Los Angeles, CA, USA). The results were presented with the corresponding standard deviation (SD) of the mean. The Fisher exact test was used to compare the gender ratio between the groups. Age, weight, height, body mass index (BMI), blood volume, blood loss drained after 24 hours, loss of hemoglobin after 24 and 60 hours, blood loss after 24 and 60 hours, and length of hospital stay were analyzed by unpaired Student t tests. Pain (VAS) and ROM were analyzed by two-way analysis of variance (ANOVA) followed by a post-hoc Bonferroni test after a paired Student t test. A value of p < 0.05 was considered statistically significant in all of the analyses.
Results
Of the 64 patients included in study, 1 patient in the control group was excluded from the results evaluation because the surgical procedure lasted > 2 hours until total closure of the wound. Thus, 32 patients received the hemostatic agent and 31 patients did not receive it. The treatment and control groups were similar in terms of basic features, such as gender, age, weight, height, BMI, and blood volume (►Table 1).
Regarding the bleeding volume at the drain in 24 hours, there was no significant difference between the groups (Control, 276.5 mL AE 46.24 versus Sealant, 365.9 mL AE 45.73; n ¼ 63; p ¼ 0.17) (►Fig. 1).
There was no significant difference between the groups regarding the mean Hb loss in 24 hours (Control, 2.78 g/ dL AE 0.24 versus Sealant, 2.85 g/dL AE 0.24; n ¼ 63;
There was no significant difference between the groups regarding the mean Hb loss in 60 hours (Control, 3.69 g/ dL AE 0.39 versus Sealant, 3.85 g/dL AE 0.33; n ¼ 41;
There was no significant difference between the groups regarding the mean total blood loss in 24 hours (Control, 930 mL AE 78 versus Sealant, 890 mL AE 67; n ¼ 63; p ¼ 0.35) (►Fig.
4)
There was no significant difference between the groups regarding the mean total blood loss in 60 hours (Control, 1,250 mL AE 120 versus Sealant, 1,190 mL AE 96; n ¼ 41; p ¼ 0.34) (►Fig. 5).
Only one patient from the control group was transfused with a bag of packed red blood cells. No patient in the Sealant group required transfusions.
There was no significant difference between the groups regarding the length of hospital days stay (Control, 5.61 AE 0.50; n ¼ 31 versus Sealant, 4.81 AE 0.36; n ¼ 32; p ¼ 0.10) (►Fig. 6).
Regarding the VAS, although the pain decreased in both groups over time, there was no significant difference between the Control and Sealant groups (p > 0.05) (►Table 2 and ►Fig. 7)
The mean ROM over time is detailed in ►Table 3. The ROM was higher in the Sealant group compared with the Control group on the 2 nd postoperative day (p ¼ 0.01), but there was no significant difference in the 6 th week (p ¼ 0.13) (►Fig. 8)
There were no complications, that is, wound healing problems, deep vein thrombosis, or infections, in any of the groups.
Discussion
Regarding the volume of drained blood in 24 hours, we have observed a greater bleeding in the study group compared with the control group, but with no statistical significance. Skovgaard et al, 15 in a prospective, double-blind, placebocontrolled study evaluating 24 patients (48 knees) undergoing simultaneous bilateral TKA, in which 1 knee received a topical, 10-mL application of Evicel fibrin sealant, and the other knee received saline solution, did not observe significant differences regarding the lost blood volume at the drain in 24 hours. Heyse et al 16 evaluated 200 patients in a prospective, double-blind, randomized TKA study in which 100 patients received a topical, 10-mL application of Evicel, and 100 patients received no further intervention. The blood loss in the drain after 24 hours was significantly higher in the study group (780 versus 673 mL; p ¼ 0.029). This higher blood loss in the study group could be explained by a "rebound effect" resulting in an increased bleeding after the degradation of this artificial clot by endogenous plasmin. We did not observe a significant difference between the groups regarding the mean Hb loss 24 and 60 hours after the surgery. Maheshawari et al 17 assessed retrospectively the efficacy of Evicel fibrin sealant (113 patients) compared with a control group (70 patients), and did not observe significant differences in Hb levels on each of the 1 st 3 postoperative days.
There was no significant difference regarding the total blood loss between the groups. Similar results were obtained by Randeli et al. 4 These authors conducted a study to verify if, compared with a control group, topical application of a new fibrin sealant (Evicel) in patients undergoing primary TKA would reduce the perioperative blood loss. A total of 62 patients were randomized to receive the topical Evicel application (n ¼ 31) or not (n ¼ 31). The perioperative blood loss was similar between the groups (1,900 mL in the control group, and 1,800 mL in the treatment group; p ¼ 0.4). Likewise, Heyse et al 16 also found no differences in total blood loss between their groups (1,409 mL in the control group versus 1,441 in the intervention group; p ¼ 0.44). Reinhardt et al 13 observed that the total blood loss was similar in a retrospective cohort of 114 patients submitted to TKA, in which 1 group received the topical fibrin sealant (Evicel), and another group was submitted to a local infiltration containing epinephrine. Considering that local periarticular epinephrine injection reduces bleeding rates after TKA, the use of fibrin sealant may be considered effective. The author points out a possible selection bias resulting from the retrospective nature of the study and the lack of randomization. In our study, one patient from the control group and none from the study group received blood transfusions. Randeli et al 4 and Maheshwari et al 17 found similar blood transfusion rates in study and control groups, suggesting that the use of fibrin sealant has no effect on these rates. Bou Monsef et al 3 retrospectively evaluated 176 patients undergoing TKA and compared the effect of a cell saver, a fibrin sealant (Evicel 5 mL), autologous preoperative donation, and no intervention on perioperative bleeding and blood transfusion requirement. All of the strategies resulted in a significant reduction in the need for allogeneic blood transfusion over the control group, suggesting that the use of Evicel was an effective measure compared with the other therapeutic strategies.
Regarding the length of hospital stay, there was no significant difference between the groups. In the study by Randelli et al, 4 there was also no significant difference between the groups. Analyzing postoperative ROM and pain according to VAS scores over time, we did not identify any significant difference between our groups, except for ROM on the 2 nd postoperative day, which was higher in the study group; this outcome, however, was not sustained until the 6 thweek evaluation. We are not able to explain this difference. No studies in the literature have reported wound healing problems, infections, or thromboembolic complications related to the use of Evicel; similarly, none of these complications were observed in our study.
A highlight of our study is its prospective, randomized, controlled, and unicentric design, as well as the establishment of well-defined inclusion criteria; as such, the treatment and control groups were very similar in terms of basic features, such as gender, age, weight, height, BMI, and blood volume.
A limitation of our study was the loss of patients at the 3 rd day evaluation, between 60 and 72 hours postoperatively. We believed that it would not be wise to keep hospitalized patients in discharge conditions just to have these data.
Conclusions
We have concluded that human fibrin hemostatic agent free of clot-stabilizing agents was not effective in reducing the bleeding volume or blood transfusion requirements in TKA patients, and that its use was not able to interfere positively or negatively with the length of hospital stay, pain and ROM. Its use was not related to any complications. 
